Opaleye Management Inc. has made a significant move by increasing its stake in Grace Therapeutics, Inc. The firm reported acquiring a total of 10,632 shares over several transactions, reflecting its ongoing investment strategy in the pharmaceutical sector.
This update is crucial for Opaleye Management as it strengthens its position in Grace Therapeutics, a company engaged in the pharmaceutical preparations industry. The transactions occurred on October 8, 9, and 12, 2026, with shares purchased at prices ranging from $2.0175 to $2.0446.
Background
Opaleye Management Inc., incorporated in Massachusetts, is an investment management firm. The company is known for its strategic investments in various sectors, including pharmaceuticals. Grace Therapeutics, Inc., the issuer of the shares, operates in the pharmaceutical preparations industry, specifically categorized under SIC 2834.
What the Filing Says
The recent filing indicates that Opaleye Management acquired 2,077 shares on October 8, 2026, followed by 5,340 shares on October 9, and 7,215 shares on October 12. The filing states:
"Represents securities owned directly by Opaleye, L.P. As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."
Impact
This acquisition may affect Opaleye Management's investment strategy and its influence within the pharmaceutical industry. The increase in holdings suggests a positive outlook for Grace Therapeutics, which may benefit from Opaleye's backing as it navigates the competitive landscape of pharmaceutical preparations.
What's Next
The filing does not say what happens next.